• Allergan (Irvine, California) reported completing its acquisition of Swiss medical technology developer EndoArt (Lausanne, Switzerland), which manufactures telemetrically controlled implants used in the treatment of morbid obesity and other conditions, for $97 million in cash. Allergan acquired ownership of EndoArt's technology platform, including FloWatch technology, which powers the Easyband remote adjustable gastric band system, a next-generation, telemetrically-adjustable gastric banding device for the treatment of morbid obesity. EndoArt also markets another product, the Flowatch-PAB, in Europe for pulmonary artery banding in newborn infants.

• Aragon Surgical (Palo Alto, California) a venture-backed surgical device start-up, reported acquiring VeriSure (also Palo Alto). Financial terms were not disclosed. Aragon said the acquisition provides it with the LapCap, the first of a new category of laparoscopic-enabling products, the PCAD (Pneumoperitoneum Creation Assist Device). The LapCap is designed to allow a surgeon to more easily and predictably pass a Veress needle into the peritoneal cavity in order to create a pneumoperitoneum — the gas-filled space in which the surgeon operates. The company said that the device will be commercially available to U.S. surgeons within 10 months.

• CardioNet (San Diego) a provider of wireless mobile cardiac outpatient monitoring solutions, reported that it completed its previously disclosed acquisition of PDSHeart (West Palm Beach, Florida), a cardiac event monitoring company. Terms were not disclosed. PDSHeart will operate as a CardioNet subsidiary, with corporate offices in West Palm Beach, Florida.

• Clarient (Aliso Viejo, California) reported that it will sell its Automated Cellular Imaging System (ACIS) and Trestle Instruments Systems business assets and related intellectual property to Carl Zeiss MicroImaging (G ttingen, Germany) for $11 million in cash and up to an additional $1.5 million subject to satisfaction of certain post-closing conditions. The deal also contemplates that Clarient and Carl Zeiss will each invest up to $3 million in cash or other in-kind contributions to pursue strategic joint development arrangements for novel markers and new menu applications for the ACIS product line.

• Cytyc (Marlborough, Massachusetts), a provider of surgical and diagnostic products targeting women's health and cancer diagnostics, has agreed to acquire Adiana (Redwood City, California), a private company that has developed a non-incisional alternative to tubal ligation for permanent contraception for women. Cytyc will make an initial upfront $60 million cash payment, plus milestone payments — including a payment when Adiana's system wins FDA-approval — and a four-year earn-out based on sales growth. Total payments, including the four-year earn-out, will not exceed $215 million.

• Greatbatch (Clarence, New York) reported that it will acquire substantially all of the assets of Biomec (Cleveland) for $11.4 million in cash and future additional considerations. Biomec is developing a polymer coating (biomimetic) that mimics the surface of endothelial cells of blood vessels with potential use on several medical devices, including in-dwelling central venous catheters, cardiac pacing leads, and extra-corporeal blood pump circuits in bypass surgery.

• Lifeline Biotechnologies (Reno, Nevada) reported reaching an agreement with Solos Endoscopy (Boston) to reacquire ownership, including all rights, to continue the development and marketing of the First Warning System, designed to assist in early detection of breast cancer.

• Respironics (Murraysville, Pennsylvania) reported the acquisition from IM Systems (Baltimore) of the PAM-RL device, an activity monitor device used to record and analyze periodic limb movements (PLMs). Terms of the purchase were not disclosed. The PAM-RL device provides researchers and clinicians with a method for assessing limb movements that can be used to study the efficacy of drug formulations and medical devices designed to treat RLS.

• SpectRx (Norcross, Georgia) reported that it has signed a "no shop" agreement and a non-binding letter of intent to sell its SimpleChoice insulin pump infusion set business. The agreement was signed with one of several unnamed parties that the company said have expressed interest in purchasing or licensing the SimpleChoice portfolio. The company said it expects to complete the transaction some time this year. The planned sale of the business is part of a previously disclosed reorganization of the company around its non-invasive cancer detection technology.

• Wright Medical Group (Arlington, Tennessee) has agreed to acquire the reconstructive foot surgery business of Darco International (Huntington, West Virginia) for about $17 million in cash. The deal is expected to close in the early part of the second quarter. Darco's reconstructive product line consists of procedure-specific plating systems, including the MRS (Modular Rearfoot), MFS (Modular Forefoot) and FRS (Forefoot Reconstructive) systems.

No Comments